Clinical Trial Search

Primary: Change From Baseline in Weighted Mean Forced Expiratory Volume in One Second (FEV1) Over 0 to 24 Hours Post-dose at the End of the 12-week Treatment Period — 0.366…

Primary: Number of Seroprotected Subjects for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies. — 154; 165; 160; 197 Participants

Primary: Percentage of Participants Achieving Low Disease Activity Score — 100 percentage of participants

Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 56 — -17.8; -23.7; -25.5 score on a scale — p=0.070

Primary: Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale — 161; 182 Participants — p=0.1994

Primary: Percentage of Participants With Pathological Complete Response (pCR) — 22.22 percentage of participants

Primary: Proportion of Subjects With a Demethylation Response at Each Dose Level — .22; .30 proportion of participants

Primary: Effectiveness of Niaspan — 41.9755 mg/dL

Primary: PET Response Rate in Metastatic Prostate Cancer Patients Treated With Zoledronate Therapy. — .091 Proportion of participants with response

Primary: Treatment Engagement — 23; 11; 6 participants — p=<0.001

Primary: LCM vs CDM: Disease Progression to a New WHO Stage 4 Event or Death — 47; 39 participants — p=0.59

Primary: Rate of Enrollment — 9.6 Months

Primary: Number of Participants With Incidence of Composite Efficacy Failure — 76; 62; 59; 34 Participants

Primary: Survival — 37; 31 participants

Primary: Serum Cholesterol to Total Sterol Ratio — 90.82; 93.99 percent total cholesterol — p=0.002